Opiant Pharmaceuticals Long Term Debt

Opiant Pharmaceuticals (OPNT) currently reports a long-term debt of $14M as of September 2022. That compares with $20M in the prior-year period — down 26.6% year over year. Use the charts on this page to explore Opiant Pharmaceuticals's long-term debt history and peer comparisons.

Opiant Pharmaceuticals's long-term debt decreased from $20M to $14M — a 26.6% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Opiant Pharmaceuticals reported $14M in long-term debt as of September 2022. That compares with $20M in the prior-year period — down 26.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Opiant Pharmaceuticals, and consider following OPNT for alerts when major investors trade the stock.

Opiant Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OPNT with unrelated industries.